Cointime

Mustang Bio

company

About

Mustang Bio is a clinical-stage biopharmaceutical company .

  • 51 - 100

Highlights

Total Funding Amount
$22M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$20M
Industries
Biotechnology,Pharmaceutical
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active

Mustang Bio is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient's own immune system to eliminate cancer cells. The products under development are - CD123, CD20, and CS1.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$22M
Mustang Bio has raised a total of $22M in funding over 2 rounds. Their latest funding was raised on Nov 1, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 1, 2021 Grant $2M 1 — — Detail
Apr 1, 2019 Post-IPO Debt $20M 1 Horizon Technology Finance — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Mustang Bio is funded by 2 investors. Horizon Technology Finance and National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Yes Post-IPO Debt
National Institutes of Health — Grant
Cointime
เนื้อหา
บริษัท